Background: Intraabdominal fibromatosis is a rare tumor-like lesion of uncertain etiology.
Case: A 49-year-old woman underwent abdominal hysterectomy and bilateral salpingooophorectomy in 1997 to treat uterine leiomyomata and ovarian fibromatosis. Postoperatively, she received estradiol 2 mg daily as hormone replacement therapy (HRT). In 2000, laparotomy performed for a large pelvic tumor revealed inoperable intraabdominal fibromatosis. The tumor, which was positive for estrogen and progesterone receptors, resolved during aromatase inhibitor therapy. The first follow-up computed tomographic (CT) scan revealed that the tumor masses were significantly reduced in size, and successive CT scans revealed stable disease.
Conclusion: Intraabdominal fibromatosis that expresses estrogen and progesterone receptors may respond favorably to treatment with aromatase inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0029-7844(03)00674-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An intra-abdominal desmoid tumour: Case report.
Int J Surg Case Rep
January 2025
Department of Obstetrics and Gynecology, Tahar Sfar University Hospital, 5111 Mahdia, Tunisia.
Introduction And Importance: Desmoid tumours typically arise in the abdomen and extremities. They are rare, originating from mesenchymal cells, with intra-abdominal desmoid tumours (DT) being even less common. While non-malignant and non-metastatic, they can be locally invasive, often necessitating surgical intervention for complete resection.
View Article and Find Full Text PDFAbdominal and intra-abdominal fibromatoses: Outcomes over time.
Am J Clin Pathol
January 2025
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, FL, US.
Objectives: Abdominal wall and intra-abdominal fibromatoses are locally aggressive, nonmetastasizing neoplasms. Surgery has been the mainstay of local control, but new forms of therapy have been developed that may influence the clinical course and morbidity. We studied the clinical features and outcomes of patients with abdominal and intra-abdominal fibromatoses over time.
View Article and Find Full Text PDFMRI features that predict progression of residual disease after ablation of extra-abdominal desmoid fibromatosis.
Eur Radiol
January 2025
Department of Radiology, Stanford School of Medicine, Stanford, CA, 94305, USA.
Objective: To identify MRI features of desmoid tumors (DTs) that predict the growth of residual disease following ablation.
Methods: Patients who underwent MRI-guided ablation for DTs between February 2013 and April 2021 were included in this single-center IRB-approved retrospective study. MRI scans assessed three suspicious tissue features: intermediate T2 signal [+iT2], nodular appearance [+NOD], and contrast enhancement [+ENH].
Mesenteric fibromatosis as an irreducible inguinal hernia.
BMJ Case Rep
January 2025
Department of Surgery, University of the Philippines, Philippine General Hospital, Manila, Philippines.
We present the case of a man in his 60s with hypertension, who had a 3-year history of an irreducible mass in the left inguinal area. The patient presented at the emergency room with left lower quadrant pain and scrotal pain. The clinical examination was not suggestive of an acute abdomen.
View Article and Find Full Text PDFRisk factors and protective measures for desmoid tumours in familial adenomatous polyposis: retrospective cohort study.
BJS Open
December 2024
Unit of Hereditary Digestive Tract Tumours, Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan, Italy.
Background: Familial adenomatous polyposis is a cancer-predisposing syndrome caused by germline pathogenic variants of the adenomatous polyposis coli gene, leading to numerous colorectal polyps and a high risk of colorectal cancer. Desmoid tumours have become significant in the management of familial adenomatous polyposis after a colectomy, yet the exact incidence remains undetermined due to a lack of dedicated surveillance.
Methods: This retrospective study accessed data from the prospectively maintained Hereditary Digestive Tumours Registry from 2000 to 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!